Evolus (EOLS) Common Equity (2017 - 2026)
Evolus (EOLS) posted Common Equity of -$28.8 million for Q1 2026, down 24.56% on a QoQ basis from -$23.1 million in Q4 2025, and down 335.81% year-over-year from $12.2 million in Q1 2025.
Evolus (EOLS) Common Equity (2017 - 2026) Analysis & Trends
Evolus' Common Equity history runs 10 years deep, the most recent figure standing at -$28.8 million for Q1 2026.
- Quarterly Common Equity fell 335.81% year-over-year to -$28.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$28.8 million (down 335.81% YoY) and the FY2025 annual result came in at -$23.1 million, down 518.44% from the prior year.
- Common Equity was -$28.8 million for Q1 2026 at Evolus, down from -$23.1 million in the prior quarter.
- Across five years, Common Equity topped out at $67.2 million in Q1 2022 and bottomed at -$28.8 million in Q1 2026.
- A 5-year average of $3.8 million and a median of $5.5 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2024 — Common Equity surged 377.38% — and 2025, when it plunged 588.29%.
- Evolus' Common Equity stood at $18.5 million in 2022, then plunged by 211.84% to -$20.7 million in 2023, then surged by 126.69% to $5.5 million in 2024, then tumbled by 518.44% to -$23.1 million in 2025, then dropped by 24.56% to -$28.8 million in 2026.
- Business Quant data shows EOLS's Common Equity at -$28.8 million in Q1 2026, -$23.1 million in Q4 2025, and -$28.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 21.93 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.23 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 3.23 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 47.38 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 5.90 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 56.13 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 3.41 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.50 Bn |
| 10 | Evolus | 390.47 Mn | 340.68 Mn | 48.90 Mn | -28.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.78 Mn |
| Dec 31, 2025 | -23.11 Mn |
| Sep 30, 2025 | -28.76 Mn |
| Jun 30, 2025 | -18.65 Mn |
| Mar 31, 2025 | -6.60 Mn |
| Dec 31, 2024 | 5.52 Mn |
| Sep 30, 2024 | 5.89 Mn |
| Jun 30, 2024 | 19.31 Mn |
| Mar 31, 2024 | 18.44 Mn |
| Dec 31, 2023 | -20.69 Mn |
| Sep 30, 2023 | -19.37 Mn |
| Jun 30, 2023 | -6.96 Mn |
| Mar 31, 2023 | 6.95 Mn |
| Dec 31, 2022 | 18.50 Mn |
| Sep 30, 2022 | 29.22 Mn |
| Jun 30, 2022 | 46.86 Mn |
| Mar 31, 2022 | 67.25 Mn |
| Dec 31, 2021 | 81.88 Mn |
| Sep 30, 2021 | 97.40 Mn |
| Jun 30, 2021 | 106.14 Mn |